Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

The oncologist·2026
Same author

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.

JAMA oncology·2026
Same author

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol.

PloS one·2026
Same author

NSCLC in Vulnerable and Special Populations: Toward Personalized Care.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Thymic tumours: an update.

Valentina Polo1, Nicolas Girard, Benjamin Besse

  • 1Gustave Roussy, Department of Cancer Medicine, Villejuif, France; Oncologic Venetian Institute, Department of Second Medical Oncology, Padua, Italy.

Presse Medicale (Paris, France : 1983)
|September 4, 2013
PubMed
Summary
This summary is machine-generated.

Thymic malignancies are rare cancers with diverse features. Current treatment guidelines for these uncommon tumours rely on limited data, highlighting the need for collaborative research to improve patient outcomes.

More Related Videos

Formation of Human Thymus Organoids in Three-Dimensional Fibrin Hydrogels
03:31

Formation of Human Thymus Organoids in Three-Dimensional Fibrin Hydrogels

Published on: October 4, 2024

Isolation and Transplantation of Different Aged Murine Thymic Grafts.
05:47

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Published on: May 13, 2015

Related Experiment Videos

Last Updated: May 8, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Formation of Human Thymus Organoids in Three-Dimensional Fibrin Hydrogels
03:31

Formation of Human Thymus Organoids in Three-Dimensional Fibrin Hydrogels

Published on: October 4, 2024

Isolation and Transplantation of Different Aged Murine Thymic Grafts.
05:47

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Published on: May 13, 2015

Area of Science:

  • Oncology
  • Thoracic Surgery

Background:

  • Thymic malignancies are uncommon neoplasms with significant heterogeneity.
  • Rarity leads to limited data for treatment guidelines, often based on small or retrospective studies.
  • Existing management strategies face ongoing controversies due to data limitations.

Purpose of the Study:

  • To outline the fundamental principles guiding the treatment of thymic malignancies.
  • To emphasize the need for a multidisciplinary approach in managing these rare tumours.

Main Methods:

  • Review of existing literature and clinical guidelines for thymic malignancies.
  • Focus on established treatment principles and areas of controversy.

Main Results:

  • Thymic malignancies present diverse clinical, pathological, and molecular characteristics.
  • Current treatment indications are derived from limited institutional data, necessitating careful interpretation.
  • Multidisciplinary care is crucial for optimal management.

Conclusions:

  • Improved understanding and management of thymic malignancies will benefit from multi-institutional collaboration.
  • Future research collaborations are essential to overcome data limitations and refine treatment strategies.